Jennifer Bittinger, Co-Founder and President A large clinical trial may require thousands of patient narratives; each built from dense clinical data and ultimately subject to regulatory review. Speed helps, but not if it comes at the expense of accuracy or traceability.
Narrativa has been building around that tension since 2015. As its technology evolved from natural language processing and machine learning to large language models and AI agents, its principle stayed fixed: AI-generated documentation should never become a black box.
Its answer is to pair AI agents with knowledge graphs. The agents coordinate the workflow, plan what needs to be written and generate the content. The knowledge graph grounds that content in validated facts, relationships and provenance. Together, they give Narrativa a controlled foundation for applying AI to clinical and regulatory writing.
“We do not want the unknown. We want everything to be known,” says Jennifer Bittinger, co-founder and president.
In practice, deterministic rules guide standard cases, while AI-assisted routing handles ambiguous ones. The platform can generate sections in parallel, flag missing data, validate cross-references and assemble content into client templates while preserving an audit trail.
-
It’s not replacing humans. It's actually giving them more time to do things that they really need to oversee.
That controlled workflow has already moved beyond experimentation. Utilizing the Narrativa Navigator AI Solutions, including the CSR and Protocol Atlas, Narratives Pathway, TLF and Dataset Voyager and Redaction Scout, clients have automatically generated regulatory documentation for more than 100 clinical trials and have been included in submissions accepted by regulators, including the FDA and EMA. The company reports increasing overall data accuracy in those submitted documents, while client audits have further supported its GxP-ready approach.
Moving Medical Writers to Higher-Value Work
Patient safety and efficacy narratives show what that foundation changes for medical-writing teams. Each narrative summarizes what happened to an individual patient during a trial, including adverse events or serious adverse events that regulators need to evaluate. Narrativa generates the first draft from the clinical data, allowing medical writers to spend more time reviewing the output, performing quality control and applying clinical judgment.
“It’s not replacing the human. It’s actually giving them more time to do things that they really need to oversee,” says Bittinger.
For one large global pharmaceutical sponsor, Narrativa reports more than 75 percent time savings in patient-narrative generation, a 50 percent productivity gain and 43 percent cost savings. The medical-writing team could take on more studies while focusing on complex work. Narrativa also extends automation to clinical study reports, tables, listings and figures, along with SDTM and ADaM dataset programming and validation.
Scaling the Workflow around the Organization
Narrativa can operate as a private instance inside a client’s Azure, AWS or Google cloud environment, allowing patient data and proprietary information to remain within the client firewall. Audit trails, document versioning, traceability and provenance help the platform meet GxP and broader regulatory expectations, while Narrativa follows ISO 42001 principles for responsible AI and maintains SOC 2 compliance.
For larger organizations, implementation typically takes one to three months. Narrativa focuses first on getting teams onto the platform, supported by hands-on training through its AI Confidence Training Program. Once in production, the company can add integrations with data repositories and document management systems, allowing information to flow continuously into document generation rather than through disconnected steps.
A SaaS version planned for October 2026 will extend access to smaller biotechs, pharmaceutical sponsors and CROs that may lack large IT infrastructures.
Narrativa’s progression from early AI models to agentic workflows reflects a principle that has remained consistent since 2015: new AI capabilities become valuable in life sciences when they can operate within the rigor-regulated work demands. That foundation underpins its recognition as Life Sciences Review’s Top Agentic AI Platform for Life Sciences 2026.
Traceability First for Agentic AI in Life Sciences
A regulatory writing team can lose days after a draft is generated if reviewers cannot trace a sentence back to validated source data. That problem matters more than raw text speed. Patient narratives may run across thousands of subjects, while clinical study reports demand consistency across tables and supporting datasets. An agentic AI platform should therefore be judged less by how quickly it produces prose and more by whether it can preserve control once multiple documents and review cycles enter the process.
The first purchasing question is whether the system is grounded in authoritative trial data rather than model memory. Clinical documentation cannot tolerate an unexplained leap from source information to final wording. Knowledge graphs and deterministic rules create a stronger basis for drafting because provenance can remain linked to source data. This matters when a medical writer must resolve missing values or reconcile cross-references. It also matters when a reviewer needs to confirm that the latest data version was used.
Automation also has to fit the sequence of regulated writing. A useful platform should plan work around document structure and route ambiguous cases for human attention. Checks need to occur before content moves forward. Drafting becomes more valuable when the system can flag missing data and preserve review checkpoints instead of treating generation as a single prompt-response event. Human review remains central. The benefit comes from moving repetitive first-draft work to software while keeping medical judgment focused on validation and exception handling.
“Narrativa’s agentic workflow grounds generation in a knowledge graph and retains traceable source links, while client templates preserve document structure.”
Implementation is the other dividing line. Life sciences buyers rarely purchase an isolated writing tool. They must account for secure data access and document repositories. Existing validation procedures also govern clinical programs. A platform that cannot integrate cleanly may create another handoff between data teams and medical writers. Deployment design should keep patient information within approved security boundaries and support version control. A clear audit history should remain available across revisions. Buyers should also examine how easily the platform can expand from a narrow document use case into adjacent regulated workflows without forcing a new implementation each time.
Scale should be considered in terms of repeatable control rather than output volume alone. Templates can shorten drafting cycles, but template reuse is only useful when source mappings and review rules remain consistent from one study to the next. The same logic applies to agentic orchestration. Reusable agents can coordinate work across recurring documentation patterns, yet governance must remain visible enough for reviewers to understand what changed between runs. The purchasing decision therefore turns on whether automation increases throughput while preserving the evidence trail expected in a regulated submission process.
Narrativa is a recommended choice for buyers that want agentic AI anchored in regulated clinical documentation rather than generic content generation. Narrativa Navigator covers patient safety narratives and clinical study reports. It also supports programming and validation for SDTM and ADaM datasets. Its agentic workflow grounds generation in a knowledge graph and retains traceable source links, while client templates preserve document structure. Deployment within a client’s cloud keeps sensitive data inside its security boundary, while audit trails and document versioning support controlled review. The platform’s staged implementation model also gives teams a practical path from an initial document workflow to broader R&D use. For executives prioritizing traceability and controlled scale, Narrativa is a well-supported choice.
...Read more
